BCRX · Biocryst Pharmaceuticals Inc
$9.55
-0.11 (-1.14%)
At close · Aug 21
Market Cap
$2.44B
Shares
255.54M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$874.84M
+94.1%
FY2025
Net Income
$263.86M
+396.9%
FY2025
Gross Margin
97.82%
+0.5pp
FY2025
Operating Margin
38.98%
+39.5pp
FY2025
Diluted EPS
$1.21
+381.4%
FY2025
Operating Cash Flow
$347.37M
+767.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $635M – $660M | $940.61M | $874.84M | $450.71M | $331.41MG | $270.83M | $157.17M | $17.81M | $48.84M | $20.65M | $25.19M | $26.35M | $48.26M | $13.61M | $17.33M | $26.29M | $19.64M | $62.38M | $74.59M | |
| — | $20.93M | $19.08M | $12.27M | $4.48M | $6.41M | $7.23M | $1.55M | $3.73M | — | $1.14M | $2.3M | $1.37M | $1000 | — | — | — | $86K | $4.54M | |
| — | $919.69M | $855.76M | $438.44M | $326.93M | $264.42M | $149.94M | $16.26M | $45.11M | — | $24.04M | $24.06M | $46.89M | $13.61M | — | — | — | $62.3M | $70.05M | |
| — | — | 97.82% | 97.28% | 98.65% | 97.63% | 95.4% | 91.3% | 92.37% | — | 95.47% | 91.28% | 97.17% | 99.99% | — | — | — | 99.86% | 93.91% | |
| — | $197.76M | $166.13M | $174.64M | $216.57M | $253.3M | $208.81M | $122.96M | $107.07M | $84.89M | $66.96M | $61.01M | $72.76M | $51.8M | $41.94M | $49.16M | $57.25M | $83.9M | $73.66M | |
| — | $12.37M | — | — | — | — | — | — | — | — | — | — | — | $7.46M | $6.01M | $9.13M | $11.98M | $11.72M | $10.12M | |
| — | $337.33M | $348.65M | $266.35M | $214.07M | $159.37M | $118.82M | $67.93M | $37.12M | $29.51M | $13.93M | $11.25M | $13.05M | $7.46M | $6.01M | — | — | — | — | |
| — | — | $1.39M | $1.25M | $1.66M | $1.44M | $777K | $748K | $724K | $770K | $704K | $483K | $180K | $177K | $304K | $628K | $886K | $2.27M | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$97K | $1.76M | — | $1.03M | — | |
| — | $1.25B | $533.85M | $453.26M | $435.12M | $419.26M | $334.89M | $192.57M | $148.29M | $114.87M | $82.6M | $74.96M | $87.7M | $59.38M | $48.05M | $60.18M | $69.23M | $96.74M | $88.33M | |
| — | -$313.16M | $340.99M | -$2.54M | -$103.71M | -$148.44M | -$177.72M | -$174.76M | -$99.46M | -$94.22M | -$57.41M | -$48.61M | -$39.44M | -$45.77M | -$30.72M | -$33.89M | -$49.59M | -$34.36M | -$13.74M | |
| — | — | 38.98% | -0.56% | -31.29% | -54.81% | -113.08% | -981.12% | -203.66% | -456.2% | -227.95% | -184.45% | -81.74% | -336.35% | -177.24% | -128.89% | -252.44% | -55.08% | -18.42% | |
| — | — | $342.38M | -$1.3M | -$102.05M | -$147M | -$176.94M | -$174.01M | -$98.73M | -$93.45M | -$56.71M | -$48.12M | -$39.26M | -$45.59M | -$30.41M | -$33.26M | -$48.7M | -$32.09M | — | |
| — | $75.29M | $78.87M | $98.52M | $108.24M | $99.09M | $59.29M | $14.5M | $11.89M | $9.18M | $8.57M | $6.49M | $5.2M | $5M | $4.78M | $4.67M | $3.77M | — | — | |
| — | -$68.03M | -$73.6M | -$84.41M | -$122.52M | -$95.95M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$381.19M | $267.39M | -$86.95M | -$226.23M | -$244.38M | -$181.81M | -$182.81M | -$108.9M | — | — | — | — | — | — | — | — | — | — | |
| — | $3.49M | $3.53M | $1.93M | $310K | $2.73M | $2.25M | $0 | $0 | $0 | $0 | $0 | $0 | $17.31M | $8.57M | $7M | — | — | — | |
| — | -$384.67M | $263.86M | -$88.88M | -$226.54M | -$247.12M | -$184.06M | -$182.81M | -$108.9M | -$101.25M | -$65.78M | -$55.14M | -$43.02M | -$45.19M | -$30.11M | -$39.08M | -$56.95M | -$33.85M | -$13.45M | |
| — | — | 30.16% | -19.72% | -68.36% | -91.24% | -117.11% | -1026.35% | -222.99% | -490.25% | -261.18% | -209.25% | -89.15% | -332.08% | -173.72% | -148.64% | -289.91% | -54.27% | -18.03% | |
| — | -$386.85M | $262.98M | -$89.3M | -$225.23M | -$247.27M | -$183.89M | -$182.85M | -$108.56M | -$101.31M | -$66.01M | -$54.95M | -$43.1M | -$45.32M | -$30.13M | -$39.09M | -$57.01M | -$33.72M | — | |
| USD/shares | — | — | $1.26 | -$0.43 | -$1.18 | -$1.33 | -$1.03 | -$1.09 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | $1.21 | -$0.43 | -$1.18 | -$1.33 | -$1.03 | -$1.09 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 209.89M | 206.7M | 192.2M | 185.91M | 179.12M | 167.27M | — | — | — | — | — | 66.77M | 55.22M | 49.47M | — | — | — |
| shares | — | — | 218.58M | 206.7M | 192.2M | 185.91M | 179.12M | 167.27M | 115.6M | 103.19M | 84.45M | 73.7M | 72.9M | 66.77M | 55.22M | 49.47M | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2011: $221K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.11×
EV/EBIT
—
Peer median 16.50×
P/E (TTM)
—
Peer median 17.42×
Peer medians compare against the 45 similar-size Drug Manufacturers - Specialty & Generic companies (of 104 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $874,837,000 | $450,712,000 | $331,412,000 | $270,827,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $623,151,000 | $442,668,000 | $324,696,000 | $267,710,000 | $136,350,000 | $3,301,000 | $17,533,000 | — |
| ORLADEYO | $601,839,000 | $437,660,000 | $325,990,000 | $251,633,000 | $122,555,000 | — | — | — |
| License and Other Revenues | $251,686,000 | $8,044,000 | $6,716,000 | — | — | — | — | — |
| License | $243,980,000 | $0 | $0 | — | — | — | — | — |
| Other Income from Contract with Customer | $29,018,000 | $13,052,000 | $5,422,000 | $19,194,000 | $34,615,000 | — | — | — |
| Collaborative and Other Research and Development | $7,706,000 | $8,044,000 | $6,716,000 | $3,117,000 | $20,820,000 | $11,130,000 | $24,999,000 | $14,552,000 |
| Milestone | — | — | — | $0 | $15,000,000 | $0 | — | — |
| Royalty | — | — | — | $2,903,000 | -$100,000 | $3,381,000 | $6,303,000 | $6,101,000 |
Key facts
CIK
882796
CUSIP
09058V103
13F (30d)
295 filings
288 filers
Visit website
Investor relations